These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21182461)

  • 1. Antiretroviral therapy-associated diseases are common in the long-term.
    Lanzafame M; Lattuada E; Zoppini G; Vento S
    AIDS Res Hum Retroviruses; 2011 Sep; 27(9):931-2. PubMed ID: 21182461
    [No Abstract]   [Full Text] [Related]  

  • 2. Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk.
    Barbaro G; Barbarini G
    Chemotherapy; 2006; 52(4):161-5. PubMed ID: 16675900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: a prospective study.
    Manosuthi W; Lueangniyomkul A; Mankatitham W; Chimsuntorn S; Tantanathip P; Thongyen S; Suntisuklappon B; Nilkamhang S; Sungkanuparph S
    J Infect; 2011 May; 62(5):406-9. PubMed ID: 21382413
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].
    Zhou H; Zheng Y; He Y; Gong G; Chen Z; Liu M; Yin W; Liu C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Aug; 34(8):731-7. PubMed ID: 19734579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HAART influences the lipids].
    Behrens G
    MMW Fortschr Med; 2009 Apr; 151(18):36-8. PubMed ID: 19769073
    [No Abstract]   [Full Text] [Related]  

  • 6. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk.
    Barbaro G
    Am J Ther; 2006; 13(3):248-60. PubMed ID: 16772767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin Resistance and the cardiometabolic syndrome in HIV infection.
    Bevilacqua M; Dominguez LJ; Barbagallo M
    J Cardiometab Syndr; 2009; 4(1):40-3. PubMed ID: 19245515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C.
    Macías J; Neukam K; Portilla J; Iribarren JA; de Los Santos I; Rivero A; Márquez M; Delgado M; Téllez F; Merino D; Giner L; von Wichmann MA; Pineda JA;
    J Antimicrob Chemother; 2011 Jun; 66(6):1346-50. PubMed ID: 21398295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low incidence of renal impairment observed in tenofovir-treated patients.
    O'Donnell EP; Scarsi KK; Darin KM; Gerzenshtein L; Postelnick MJ; Palella FJ
    J Antimicrob Chemother; 2011 May; 66(5):1120-6. PubMed ID: 21393145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HAART-associated body habitus and metabolic changes, Part 2.
    Liss M; Boyle BA
    AIDS Read; 2000 Dec; 10(12):688-91. PubMed ID: 11189733
    [No Abstract]   [Full Text] [Related]  

  • 11. Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.
    Boyle BA; Cohen CJ; DeJesus E; Elion R; Frank I; Moyle GJ; Sax PE
    AIDS Read; 2009 Apr; 19(4):158-60. PubMed ID: 19388184
    [No Abstract]   [Full Text] [Related]  

  • 12. Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV.
    Boehme RE; Cameron S
    Antivir Ther; 2009; 14(8):1195-208. PubMed ID: 20032550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complications of HIV infection in an ageing population: challenges in managing older patients on long-term combination antiretroviral therapy.
    Zhao H; Goetz MB
    J Antimicrob Chemother; 2011 Jun; 66(6):1210-4. PubMed ID: 21421583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and prevalence of the metabolic syndrome in a cohort of naive HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy.
    Palacios R; Santos J; González M; Ruiz J; Márquez M
    Int J STD AIDS; 2007 Mar; 18(3):184-7. PubMed ID: 17362552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretrovirals and cardiovascular disease: is HAART bad for your heart?
    Fichtenbaum CJ
    AIDS Clin Care; 2003 Aug; 15(8):69-73, 76. PubMed ID: 12945527
    [No Abstract]   [Full Text] [Related]  

  • 16. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy.
    Smith KY
    J Infect Dis; 2002 May; 185 Suppl 2():S123-7. PubMed ID: 12001033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What does the term "HIV-associated lipodystrophy" mean?
    Marcason W
    J Am Diet Assoc; 2009 Feb; 109(2):364. PubMed ID: 19167963
    [No Abstract]   [Full Text] [Related]  

  • 19. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.
    Pozniak A; Gazzard B; Anderson J; Babiker A; Churchill D; Collins S; Fisher M; Johnson M; Khoo S; Leen C; Loveday C; Moyle G; Nelson M; Peter B; Phillips A; Pillay D; Wilkins E; Williams I; Youle M;
    HIV Med; 2003 Oct; 4 Suppl 1():1-41. PubMed ID: 14511246
    [No Abstract]   [Full Text] [Related]  

  • 20. [Coronary heart disease associated with the use of highly active antiretroviral therapy (HAART). A case report and review].
    Neumann T; Kondratieva J; Eggebrecht H; Wieneke H; Esser S; Bartel T; Erbel R
    Herz; 2005 Sep; 30(6):504-9. PubMed ID: 16170681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.